Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15951328.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neuropathic pain sometimes needs invasive pain therapy. We present the case of a patient with cancer-related neuropathic pain untreatable with conventional pain therapy after tumour-embolization. The patient was treated successfully with intrathecal (i.t.) administration of S(+)-ketamine, in addition to morphine. Plasma concentrations of S(+)-ketamine were measured regularly throughout the treatment. Continuous i.t. administration of S(+)-ketamine over a period of 3 months demonstrated low plasma levels and no unwanted side-effects.
Medical subject headings
- Analgesics
- Ketamine
- Intractable Pain
- Palliative Care
- Urethral Neoplasms